10x Genomics is trading 5.9% higher at $82.62; biotech-sector strength is the best available context, not a confirmed direct cause. - No clear company-specific announcement explaining the October 28 move surfaced in available search results; headlines found were valuation commentary and previously announced events. - XBI rose 2.18% during the regular session amid positive clinical-trial and regulatory news elsewhere in biotech; supplied market-index moves were modest. - Confidence is medium.